Trials (first author, year) | Location | Design of trial | Duration (months) | Original patients (eyes) | Dropout patients (eyes) | Mean age±SD (range) (male/female) | System baselines | Ocular baselines | Jadad score |
Yeh, 20091 | Taiwan | Prospective, comparative case–control clinical study | 6 |
|
|
| NS: DM, Systematic hypertension, Renal insufficiency, haemodialysis | NS: Lens status, Prior PRP, BCVA | 1 |
da R Lucena, 20092 | Brazil | Prospective, randomised comparative laboratory study | That day |
| 0 |
| NS: DM, HbA1C;RD duration | NS: Prior PRP, BCVA | 4 |
Rizzo, 20083 | Italy | Consecutive, randomised prospective study | 6 |
| 0 | Total: 52 (24–63) | NR | NS: CS, BCVA | 4 |
Modarres, 20094 | Iran | Prospective surgeon-masked randomised clinical trial | 7±3.6 |
| 0 |
| NR | NS: CS, BCVA | 4 |
Ahmadieh, 20095 | Iran | Prospective, randomised, double-masked clinical trial | 1 |
|
|
| NS: systematic hypertension, renal failure, aspirin consumption, smoking | NS: Prior PRP, VH, BCVA | 7 |
Yang, 20086 | Taiwan | Prospective, non-randomised, comparative case study | 6 |
| 0 |
|
| NS: lens status, Prior PRP, BCVA | – |
di Lauro, 20109 | Italy | Prospective, randomised controlled trial | 6 |
| 0 | NR | NR | NS: BCVA, CSS | 3 |
1–, vitrectomy alone group; 2–, vitrectomy with intravitreal bevacizumab pretreatment; BCVA, best-corrected visual acuity; CS, complexity score (classify the severity of PDR); CSS, complexity surgery score; DM, diabetes mellitus; HbA1C, glycosylated haemoglobin A1C; IVB, intravitreal bevacizumab; NR, not reported; NS, not significant.; PRP, panretinal photocoagulation; RD, retinal detachment; VH, vitreous haemorrhage.